Almac Pharma Services Joins European Paediatric Formulation Initiative (EuPFI)

Charnwood, UK - 30 Aug 2024 - Almac Pharma Services, a member of the privately owned Almac Group providing innovative pharmaceutical development, manufacture and commercial services to global pharmaceutical and biotech organisations, is proud to announce it has become a member of the European Paediatric Formulation Initiative (EuPFI).

EuPFI is a consortium dedicated to formulating better medicines for children. Their workstreams focus on critical aspects of pediatric formulation development, including age-appropriate formulations, administration devices, taste masking, pharmaceutical excipients, and biopharmaceutics.

As part of EuPFI, Almac Pharma Services' can contribute to improving access to paediatric medicines by sharing their expertise in this field and collaborating with other industry, academic and regulatory expert partners to identify innovative solutions to the challenges associated with developing medicines for children. By aligning with EuPFI's mission, Almac will continue its contribution to improving pediatric healthcare worldwide.

Prof Catherine Tuleu, EuPFI's Founder, added: "We are delighted to partner with Almac to advance 'little humans' health! Their unique tailor-made pharmaceutical development and commercial solutions towards paediatric & age-appropriate formulations, as well personalised medicines, is a welcome synergistic addition to our consortium."

Terry Ernest, Director of Manufacturing Science and Technology, Almac Pharma Services, commented "With over 55 years development experience across Almac, our experts specialise in the design, development, manufacture and packaging of age-appropriate drug products. Becoming a member of the EuPFI enables us to contribute meaningful insights and collaborate with other members as we work together to advance pediatric medicine."